MEI Pharma Inc (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced on Friday that it has promoted Richard Ghalie, MD as its new chief medical officer.

Ghalie will succeed Robert Mass, MD, who is retiring from the company.

Ghalie was named senior vice president, clinical development in March 2016. He has over 25 years of drug development experience at public and private companies and is a hematologist and oncologist. He has served in various executive positions in the pharmaceutical industry and has led medical teams that successfully filed NDAs and MAAs resulting in the approval of four new indications.